Revlimid for Thyroid Cancer – pro
Rapidly-progressive, distantly metastatic thyroid cancers, unresponsive to I-131, are lethal and haven’t known effective systemic therapies. A prior thalidomide trial in this context had 50% response rate (PR + SD), 6 months mean durability and significant toxicity. An open-label phase II trial was recently published that included of 25 adult patients with distantly metastatic, I-131-unresponsive (papillary, follicular, or insular) thyroid cancers with >30% tumor volume progression documented within 12 months of entry, receive 25 mg oral lenalidomide daily. 67% were responders (44% SD, 22% PR). Of 10 patients enrolled by 1/07, 6 were responders (2 PR, 4 SD) with 3 maintaining response to date (>12 months). The authors concldued that Lenalidomide is well tolerated and ferther studies were needed.
Revlimid is in trials for thyroid cancer. REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas, NCT00287287. The primary objective of this ongoing study is to assess the anti-tumor activity of REVLIMID® (lenalidomide), administered as a single agent, in patients with distantly metastatic thyroid carcinomas which are unresponsive to systemic radioiodine, in terms of tumor response and response duration.
Ain, K. B., Lee, C., Holbrook, K. M., Dziba, J. M., Williams, K. D.
Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results
J Clin Oncol (Meeting Abstracts) 2008 26: 6027
Ain, K. B., Lee, C., Holbrook, K. M., Dziba, J. M., Williams, K. D.
Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results
J Clin Oncol (Meeting Abstracts) 2008 26: 6027